Drug effects on dreaming

Sleep and Sleep Disorders: A Neuropsychopharmacological Approach

Volumn , Issue , 2006, Pages 256-261

  Agargun, Mehmet Yucel ^a   Ozbek, Hanefi ^a  

^a YUZUNCU YIL UNIVERSITY   (Turkey)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84856111159     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1007/0-387-27682-3_29     Document Type: Chapter

References (63)

1. Maquet P, Franck G. REM sleep and the amygdala. Molecular Psychiatry 1997; 2:195-196.
2. Braun AR, Balkin TJ, Wesenten NJ et al. Regional cerebral blood flow diroughout die sleep-wake cycle. An H2(15)0 PET study. Brain 1997; 120:1173-1197.
3. Nofzinger EA, Mintun MA, Wiseman MB et al. Forebrain aaivation in REM sleep: An FDG PET study Brain Research 1997; 770:192-201.
4. Maquet P. Functional neuroimaging of normal human sleep by positron emission tomography. J Sleep Res 2000; 9:207-231.
5. Solms M. Dreaming and REM sleep are controlled by different brain mechanisms. Behav Brain Sci 2000; 23:843-850.
6. McNamara P, Durso R, Auerbach S. Dopaminergic syndromes of sleep, mood and mentation: Evidence from Parkinsons disease and related disorders. Sleep and Hypnosis 2002; 4:119-131.
7. Wisor JP, Nishino S, Sora I et al. Dopaminergic role in stimulant-induced wakefulness. Journal of Neuroscience 2001; 21:1787-1794.
8. Agid Y, Javoy-Agid M, Ruberg M. Biochemistry of neurotransmitters in Parkinsons disease. In: Marsden CD, Fahn S, eds. Movement Disorders. New York: Buttersworth & Co., 1987:166-230.
9. Cipolli C, Bolzani R, Massetani R et al. Dream structure in Parkinsons patients. Journal of Nervous Mental Disorders 1992; 180:516-523.
10. Fosse R, Stickgold R, Hobson JA. Emotional experience during rapid-eye-movement sleep in narcolepsy. Sleep 2002; 25:724-732.
11. Gottesmann C. The neurochemistry of waking and sleeping mental activity: The disinhibition-dopamine hypothesis. Psychiatry and Clinical Neurosciences 2002; 56:345-354.
12. Portas CM, Bjorvatn B, Ursin R. Serotonin and the sleep/wake cycle: Special emphasis on microdialysis studies. Prog Neurobiol 2000; 60:13-35.
13. Jones BE. Paradoxical sleep and its chemical/structural substrates in the brain. Neuroscience 1991; 40:637-656.
14. McCarley RW, Massaquoi G. Neurobiological structure of the revised limit cycle reciprocal interaction model of REM cycle control. Journal of Sleep Research 1992; 1:132-137.
15. Monti JM, Jantos H, Monti D et al. Dorsal raphe nucleus administration of 5-HTlA receptor agonist and antagonists: Effect on rapid eye movement sleep in the rat. Sleep Research Online 2000; 3:29-34.
16. Sorensen E, Gronli J, Bjorvatn B et al. Sleep and waking following microdialysis perfusion of the selective 5-HTlA receptor antagonist p-MPPI into the dorsal raphe nucleus in the freely moving rat. Brain Research 2001; 897:122-130.
17. Sharpley AL, Gregory CA, Solomon RA et al. Slow wave sleep and 5-HT2 receptor sensitivity during maintenance tricyclic antidepressant treatment. Journal of Affective Disorders 2000; 19:273-277.
18. Sommerfelt L, Ursin R. The 5-HT2 antagonist ritanserin decreases sleep in cats. Sleep 1993; 16:15-22.
19. Coenen AM, Ates N, Skarsfeldt T et al. Effects of sertindole on sleep-wake states, electroencephalogram, behavioral patterns, and epileptic activity of rats. Pharmacol Biochem Behav 1995; 51:353-357.
20. Pace-Schott EF, Gersh T, Silvestri R et al. SSRI treatment suppresses dream recall frequency but increases subjective dream intensity in normal subjeas. J Sleep Res 2001; 10:129-142.
21. Hobson JA, McCarley RW, Wyzinski PW. Sleep cycle oscillation: Reciprocal discharge by two brainstem neuronal groups; Science 1975; 189:55-58.
22. Siegel JM. Brainstem mechanisms generating REM sleep. GABA release in the dorsal raphe nucleus. In: Kryger MH, Roth T, Dement WC, eds. Principles and Practice of Sleep Medicine. 3rd ed. Philadelphia: WB Saunders, 2000:724-741.
23. Kirschner N. Changes in dream content after drug treatment. Dreaming 1999; 9:195-200.
24. Ulivelli M, Rossi S, Lombardi C et al. Polysomnographic characterization of pergolide induced sleep attacks in idiopathic PD. Neurology 2002; 58:462-465.
25. Hartmann E, Russ D, Oldfield M et al. Dream content: Effects of L-Dopa. Sleep Research 1980; 9:153.
26. Rechtschaffen A, Maron L. The effect of amphetamine on the sleep cycle. Electroencephalogr Clin Neurophysiol 1964; 16:438-445.
27. Watson R, Hartmann E, Schildkraut JJ. Amphetamine withdrawal: Affeaive state sleep patterns and MHPG excretion. Am J Psychiatry 1972; 129:39-45.
28. Reimann D, Hohagen F, Fritsch-Montero R et al. Cholinergic and noradrenergic neurotransmission: Impact on REM sleep regulation in healthy subjects and depressed patients. Acta Psychiatrica Belgica 1992; 92:151-171.
29. Danguir J, De Saint-Hilaire-Kafi S. Scopolamine-induced suppression of paradoxical sleep is reversed by the somatostatin analogue SMS 201-995 in rats. Pharmacol Biochem Behav 1988; 30:295-297.
30. Hernandez-Peon R, Chavez-Ibarra G, Morgane PJ et al. Limbic cholinergic pathways involved in sleep and emotional behavior. Exp Neurol 1963; 8:93-111.
31. Callaway CW, Lydic R, Baghdoyan HA et al. Pontogeniculooccipital waves: Spontaneous visual system activity during rapid eye movement sleep. Cell Mol Neurobiol 1987; 7:105-149.
32. Gillin JC, Sutton L, Ruiz C et al. The effects of scopolamine on sleep and mood in depressed patients with a history of alcoholism and a normal comparison group. Biol Psychiatry 1991; 30:157-169.
33. Velazquez-Moctezuma J, Gillin JC, Shiromani PJ. Effects of specific Ml, M2 muscarinic receptor agonists on REM sleep generation. Brain Res 1989; 503:128-131.
34. Sitaram N, Moore AM, Gillin JC. The effect of physostigmine on normal human sleep and dreaming. Arch Gen Psychiatry Oct 1978; 35(10):1239-43.
35. Muzio JN, RoflRvarg HP, Kaufman E. Alterations in the nocturnal sleep cycle resulting from LSD. Electroencephalogr Clin Neurophysiol 1966; 21:313-324.
36. Shiromani P, Gillin JC, Henriksen SJ. Acetylcholine and the regulation of REM sleep: Basic mechanisms and clinical implications for affective illness and narcolepsy. Annu Rev Pharmacol Toxicol 1987; 27:137-156.
37. Hartmann E. The nightmare: The psychology and biology of terrifying dreams. NY: Basic Books Inc., 1984.
38. Pavel S, Goldstein R, Petrescu M et al. REM sleep induction in prepubertal boys by vasotocin: Evidence for the involvement of serotonin containing neurons. Peptides 1981; 2:245-50.
39. Siegel JM, Rogawski MA. A function for REM sleep: Regulation of noradrenergic receptor sensitivity. Brain Res Rev 1988; 13:213-233.
40. Depoorte H. Adrenergic agonists and antagonists and sleep-wakefulness stages. In: Wauquier A, Gaillard JM, Monti JM et al, eds. Sleep: Neurotransmitters and Neuromodulators. New York: Raven Press, 1985:79-92.
41. Coulter JD, Lester BK. Reserpine and sleep. Psychopharmacology 1971; 19:134-147.
42. Mignot E, Guilleminault C, Bowersox S et al. Role of central a-1 adrenoceptors in canine narcolepsy. J Clin Invest 1988; 82:885-894.
43. Aldrich MS, Rogers AE. Exacerbation of human cataplexy by prazosin. Sleep 1989; 12:254-256.
44. Hilakivi I, Leppavouri A. Effects of methoxamine, an a-1 adrenoceptor agonist, and prazosin, an a-1 antagonist, on the stages of the sleep-wake cycle in the rat. Acta Physiol Scand 1984; 120:363-372.
45. Nicholson AN, Pascoe PA. Presynaptic a-2 adrenoceptor function and sleep in man: Studies with clonidine and idazoxan. Neuropharmacology 1991; 30:367-372.
46. Oswald I, Adam K, Allen S et al. A-Adrenergic blocker thymoxamine and mesoridazine both increase human REM sleep duration. Sleep Research 1974; 3:62.
47. Hilakivi I. The role of b- And a-adrenoreceptors in the regulation of the stages of the sleep-waking cycle in the cat. Brain Res 1983; 227:109-118.
48. Roth T, Kramer M, Salis PJ. Drugs, REM sleep, and dreams. In: Wolfman BB, ed. Handbook of Dreams. NY: Van Nostrand Reinhold Co., 1979:203-225.
49. Schredl M, Schafer G, Weber B et al. Dreaming and insomnia: Dream recall and dream content of patients with insomnia. J Sleep Res 1998; 7:191-198.
50. Riemann D, Low H, Schredl M et al. Investigations of morning and laboratory dream recall and content in depressive patients during baseline conditions and under antidepressive treatment with trimipramine. Psychiatric Journal of the University of Ottawa 1990; 15:93-99.
51. Armitage R, Rochlen A, Fitch T et al. Dream recall and major depression: A preHminary report. Dreaming 1995; 5:189-198.
52. Kirschner N. Changes in dream content after drug treatment. Dreaming 1999; 9:195-200.
53. Hall CS, Van de Castle R. The Content Analysis of Dreams. NY: Appleton-Century-Crofts, 1966.
54. Koponen H, Lepola U, Leinonen E et al. Citalopram in the treatment of obsessive-compulsive disorder: An open pilot study. Acta Psychiatr Scand 1997; 96:343-346.
55. Becker RE, Dufresne RL. Perceptual changes with bupropion, a novel antidepressant. Am J Psychiatry 1982; 139:1200-1201.
56. Strayhorn JM, Nash JL. Frightening dreams and dosage schedule of tricyclic and neuroleptic drugs. J Nerv Ment Dis 1978; 166:878-880.
57. Lepkifker E, Dannon PN, lancu I et al. Nightmares related to fluoxetine treatment. Clin Neuropharmacol 1995; 18:90-94.
58. Schenck CH, Mahowald MW, Kim SW et al. Prominent eye movements during NREM sleep and REM sleep behavior disorder associated with fluoxetine treatment of depression and obsessive-compulsive disorder. Sleep 1992; 15:226-235.
59. Thompson DF, Pierce DR. Drug-induced nightmares. Ann Pharmacother 1999; 33:93-98.
60. Warner MD, Dorn MR, Peabody CA. Survey on the usefulness of trazodone in patients with PTSD with insomnia or nightmares. Pharmacopsychiatry 2001; 34:128-131.
61. Gillin JC, Smith-Vaniz A, Schnierow B et al. An open-label, 12-week clinical and sleep EEC study of nefazodone in chronic combat-related posttraumatic stress disorder. J Clin Psychiatry 2001; 62:789-796.
62. Lewis JD. Mirtazapine for PTSD Nightmares. Am J Psychiatry 2002; 159:1948-1949.
63. Hartmann E. The nightmare is the most useful dream. Sleep and Hypnosis 1999; 1:199-203.